Stock Details
SNY is Sanofi's stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 52.84$. Average daily volumn in 3 months 2.38M. Market cap 131.36B

Stock symbol : SNY. Exchange : NasdaqGS. Currency : USD
Lastest price : 52.60$. Total volume : 1.75M. Market state POSTPOST
Click reload if you want to check the lastest price on market!!!

Sanofi (SNY)
Last Price

Previous Close53.42
Day Range52.46-53.00
Bid51.64 x 1.1k
Ask53.81 x 800
Average Volume2.38M
Market Cap131.36B
52 Week Range46.93-58.10
Trailing P/E18.79
Foward P/E11.77
Dividend (Yield %)3.32%
Ex-Dividend Date2022-05-26

Financial Details

According to Sanofi's financial reports the company's revenue in 2021 were 39.17B an increase( +5.41%) over the years 2020 revenue that were of 37.37B. In 2021 the company's total earnings were 6.22B while total earnings in 2020 were 12.29B(-50%).

Loading ...


Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines ... for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Market Cap:
Total Assets:
Total Cash:

News about "Sanofi"


Sanofi's Top-Selling Drug Just Snagged Another Approval From the FDA

Source from : The Motley Fool on - 2 days ago

Mega-blockbuster Dupixent was just given the FDA's green light to treat patients with a chronic, progressive inflammatory disease.See details»


Why Sanofi May Be a Frontrunner in Endemic COVID-19

Source from : The Motley Fool on - 2 days ago

Global biopharmaceutical company Sanofi (SNY 5.95%) encountered setbacks while developing its COVID-19 vaccine, and only this year reported results from late-stage clinical trials ...See details»


Sanofi Enters into a Partnering Agreement with Health2Sync

Source from : WFMZ-TV - 7 hours ago

Through this partnering agreement, Sanofi and Health2Sync will work together to develop digitized features for healthcare providers and patients on insulin in Japan that will help improve Hypoglycemia ...See details»

Sanofi: Information concerning the total number of voting rights and shares – May 2022

Source from : YAHOO!Finance - 13 hours ago

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement ...See details»


Sanofi, GSK announce positive Covid-19 vaccine trial data

Source from : Clinical Trials Arena - 22 hours ago

Sanofi and GSK have announced positive results from the trial of their adjuvanted bivalent D614 and Beta (B.1.351) Covid-19 vaccine.See details»


Sanofi, GSK variant-specific COVID shot found effective against Omicron

Source from : Reuters - 4 days ago

Late-stage data on an experimental COVID-19 vaccine from Sanofi and GSK has showed the shot confers protection against the Omicron variant of the virus, the companies said on Friday.See details»


Sanofi, GSK say dual-acting vaccine prevents COVID-19 from omicron in large trial

Source from : BioPharma Dive - 4 days ago

A shot the partners have been developing reduced symptomatic infections associated with the variant by 72% compared to a placebo, positioning it as a potential option, if approved, to combat omicron.See details»


New Data Suggest GSK and Sanofi’s Covid Vaccine Could Pose a Challenge to Pfizer and Moderna

Source from : Barron's - 3 days ago

Sanofi and GSK joint Covid-19 vaccine has finally produced data that could challenge the dominance of the Pfizer and Moderna vaccines. In a statement early Friday, Sanofi said that a version of the ...See details»


Sanofi (NASDAQ: SNY): A Great Stock To Watch

Source from : stocksregister - 3 days ago

Sanofi (NASDAQ:SNY) shares, rose in value on Friday, June 24, with the stock price up by 4.46% to the previous day’s close as strong demand from buyers drove the stock to $52.67. Actively observing ...See details»


GSK-Sanofi Beta-containing vaccine shows efficacy against Omicron

Source from : Seeking Alpha - 4 days ago

GSK (GSK) and Sanofi (SNY) said their Beta-containing vaccine COVID-19 vaccine showed efficacy against Omicron in a late-stage study. The companies reported data from stage 2 of a ...See details»

Press Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine

Source from : Associated Press - 4 days ago

Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine. Primary vaccination withBeta-containingvaccine candidate delivers64.7 ...See details»

Sanofi, GSK say their next-generation COVID-19 booster has 72% efficacy against omicron

Source from : MarketWatch on - 3 days ago

Sanofi and GlaxoSmithKline said Friday that their experimental bivalent COVID-19 booster had a 72% efficacy rate against omicron, and they now plan to submit the data to regulators. The recombinant ...See details»


CD­C's ACIP rec­om­mends high­er dose, Se­qirus, Sanofi flu vac­cines in adults 65 and old­er

Source from : ENDPOINTS NEWS - 4 days ago

Higher dose or adjuvanted seasonal flu vaccines are better for older adults, according to a CDC advisory committee's recommendation. The CDC's Advisory Committee on Immunization Practices on Wednesday ...See details»


Veriti Management LLC Buys 5,169 Shares of Sanofi (NASDAQ:SNY)

Source from : ETF Daily News - 4 days ago

Veriti Management LLC increased its stake in Sanofi (NASDAQ:SNY – Get Rating) by 57.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange ...See details»